Kronox Lab

Why is Kronox Lab Sciences Ltd falling/rising?

As of 30-Aug, Kronox Lab Sciences Ltd's stock price is Rs 178.90, down 4.97% and has declined 17.20% over the past week. Investor interest has sharply decreased, with delivery volume dropping significantly, indicating ongoing challenges for the stock.

As of 30-Aug, Kronox Lab Sciences Ltd's stock price is falling, currently at Rs 178.90, which reflects a decrease of Rs 9.35 or 4.97%. The stock has underperformed its sector by 4.84% today and has been on a consecutive decline for the last two days, resulting in a total drop of 8.25% over this period. Additionally, the stock's performance over the past week shows a significant decline of 17.20%, while the benchmark Sensex has only decreased by 0.36% during the same timeframe.<BR><BR>Investor participation has also decreased sharply, with delivery volume on 27 August plummeting by 99.16% compared to the 5-day average, indicating a lack of interest among investors. The stock touched an intraday low of Rs 178.85, further emphasizing the downward trend. Although the stock remains net-debt free, which is a positive factor, the overall market sentiment and recent performance suggest that the stock is currently facing challenges that are contributing to its decline.

Which are the latest news on Kronox Lab?

Should I buy, sell or hold Kronox Lab Sciences Ltd?

What does Kronox Lab do?

Kronox Lab Sciences Ltd is a micro-cap company in the specialty chemicals industry, incorporated in 2008 and converted to a public company in 2019, with recent quarterly net sales of 28 Cr and net profit of 7 Cr as of June 2026. Key financial metrics include a market cap of INR 586 Cr, P/E ratio of 20.00, and a return on equity of 30.58%.

Overview: <BR>Kronox Lab Sciences Ltd operates in the specialty chemicals industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Kronox Lab Sciences Limited was incorporated in 2008 as 'Kronox Lab Sciences Private Limited' and later converted to a Public Limited Company in 2019. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 7 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 586 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 44 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 30.58% <BR>Price to Book: 7.07<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Kronox Lab?

Kronox Lab's peers include Gem Aromatics, Sudarshan Pharma, DMCC Speciality, Chembond Chemic., Chemcon Special., Jayant Agro Org., Black Rose Indus, Aarti Surfactant, and Plastiblends (I). Sudarshan Pharma shows the best growth and returns, while Kronox Lab has a below-average growth rating and a 1-year return of -3.18%.

Peers: The peers of Kronox Lab are Gem Aromatics, Sudarshan Pharma, DMCC Speciality, Chembond Chemic., Chemcon Special., Jayant Agro Org., Black Rose Indus, Aarti Surfactant, and Plastiblends (I).<BR><BR>Quality Snapshot: Excellent management risk is observed at Chembond Chemic., Chemcon Special., and Plastiblends (I), while Average management risk is found at Gem Aromatics, Sudarshan Pharma, DMCC Speciality, Jayant Agro Org., Kronox Lab, Black Rose Indus, and Aarti Surfactant. Growth ratings show Excellent growth at Sudarshan Pharma, while Below Average growth is noted at Gem Aromatics, DMCC Speciality, Chembond Chemic., Chemcon Special., Jayant Agro Org., Kronox Lab, Black Rose Indus, Aarti Surfactant, and Plastiblends (I). For Capital Structure, Excellent ratings are given to Chembond Chemic., Chemcon Special., Black Rose Indus, and Plastiblends (I), while Good ratings are found at Gem Aromatics and Jayant Agro Org., and Below Average at Sudarshan Pharma and Aarti Surfactant.<BR><BR>Return Snapshot: Sudarshan Pharma has the highest 1-year return at 20.20%, while Chemcon Special. has the lowest at -15.41%. Kronox Lab's 1-year return is -3.18%, which is higher than Chemcon Special. but lower than Sudarshan Pharma. Additionally, Aarti Surfactant is the only peer with a negative six-month return.

How big is Kronox Lab?

As of 14th August, Kronox Lab Sciences Ltd has a market capitalization of 556.00 Cr and reported net sales of 105.32 Cr and net profit of 28.57 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Kronox Lab Sciences Ltd has a market capitalization of 556.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 105.32 Cr, while the sum of Net Profit for the same period is 28.57 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds valued at 90.11 Cr and Total Assets amounting to 98.43 Cr.

Are Kronox Lab Sciences Ltd latest results good or bad?

Kronox Lab Sciences Ltd's latest results show a net profit increase of 21.40% and improved operating margins, but flat revenue growth raises concerns. Overall, the market sentiment is cautious, leading to a consensus "SELL" rating due to high valuation multiples.

Kronox Lab Sciences Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹8.00 crores for Q4 FY26, which is a significant increase of 21.40% compared to the previous quarter. Additionally, the operating margin improved to 36.43%, reflecting enhanced operational efficiency. However, the revenue for the same quarter remained flat at ₹26.13 crores, showing no year-on-year growth, which raises concerns about the company's ability to drive top-line expansion.<BR><BR>Despite the positive profit and margin improvements, the overall market sentiment appears cautious. The stock is currently trading at a price-to-earnings ratio of 19.25x and a price-to-book value of 5.53x, indicating a premium valuation that some analysts view as unjustified given the company's modest five-year sales growth rate of just 6.80%. This disconnect has led to a consensus "SELL" rating from the market.<BR><BR>In summary, while Kronox Lab has demonstrated strong profitability metrics and operational efficiency, the lack of revenue growth and high valuation multiples suggest that the latest results are not entirely positive, leading to a cautious outlook for the company.

When is the next results date for Kronox Lab Sciences Ltd?

The next results date for Kronox Lab Sciences Ltd is 21 May 2026.

The next results date for Kronox Lab Sciences Ltd is scheduled for 21 May 2026.

How has been the historical performance of Kronox Lab?

Kronox Lab has demonstrated consistent growth over the past four years, with net sales increasing from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, and profit after tax rising from 13.63 Cr to 25.47 Cr, reflecting strong profitability and improved cash flow. The company's total assets and liabilities also grew, indicating a stable financial position.

Answer:<BR>The historical performance of Kronox Lab shows a consistent growth in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Kronox Lab's net sales have increased from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, reflecting a positive growth trend. The total operating income followed a similar trajectory, rising from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25. The company's operating profit (PBDIT) also demonstrated significant growth, moving from 20.79 Cr in Mar'22 to 35.65 Cr in Mar'25, with an operating profit margin of 33.06% in the latest fiscal year. Profit before tax increased from 18.36 Cr in Mar'22 to 34.27 Cr in Mar'25, while profit after tax rose from 13.63 Cr to 25.47 Cr during the same period, resulting in a PAT margin of 25.42% in Mar'25. On the balance sheet, total assets grew from 56.46 Cr in Mar'22 to 98.43 Cr in Mar'25, with total liabilities increasing from 56.46 Cr to 98.43 Cr, indicating a stable financial position. Cash flow from operating activities improved significantly, reaching 30.00 Cr in Mar'25 compared to 9.00 Cr in Mar'22, while cash and cash equivalents at the end of Mar'25 stood at 3.00 Cr, up from 2.00 Cr in Mar'22. Overall, Kronox Lab has shown robust growth in sales, profits, and cash flow, alongside a strengthening balance sheet.

Is Kronox Lab technically bullish or bearish?

As of October 8, 2025, Kronox Lab's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish MACD, RSI, moving averages, and underperformance compared to the Sensex.

As of 8 October 2025, the technical trend for Kronox Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and Dow Theory indicates a mildly bearish outlook on both weekly and monthly timeframes. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish sentiment.

Is Kronox Lab overvalued or undervalued?

As of July 2, 2024, Kronox Lab is considered very expensive and overvalued with a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, despite a year-to-date return of -15.17% compared to the Sensex's 5.54%.

As of 2 July 2024, the valuation grade for Kronox Lab has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, which are notably high compared to industry norms.<BR><BR>In comparison to its peers, Kronox Lab's PE ratio is substantially lower than that of Solar Industries India Ltd. at 123.77 and Godrej Industries Ltd. at 46.63, but it remains elevated within its own valuation grade. The company's recent stock performance has been underwhelming, with a year-to-date return of -15.17%, contrasting sharply with the Sensex's positive return of 5.54% during the same period. This reinforces the notion that Kronox Lab is currently overvalued in the specialty chemicals sector.

Who are the top shareholders of the Kronox Lab?

The top shareholders of Kronox Lab include promoter Jogindersingh G Jaswal with 26.39%, followed by individual investors with 20.54%, and the Negen Undiscovered Value Fund at 1.71%. Additionally, four Foreign Institutional Investors hold a combined 0.04% of the shares.

The top shareholders of Kronox Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jogindersingh G Jaswal, with a stake of 26.39%. Additionally, there are four Foreign Institutional Investors (FIIs) holding a combined 0.04% of the shares. The highest public shareholder is the Negen Undiscovered Value Fund, which holds 1.71%. Individual investors collectively own 20.54% of the company.

Has Kronox Lab declared dividend?

Kronox Lab Sciences Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of August 23, 2024. Despite the dividend declaration, total returns have been mixed, showing significant negative returns in the short term and minimal returns over longer periods.

Kronox Lab Sciences Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -16.64%, the dividend return was 0%, resulting in a total return of -16.64%.<BR><BR>For the 1-year period, the price return was 0%, the dividend return was 0.33%, leading to a total return of 0.33%.<BR><BR>In the 2-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the 3-year period, there was no change in price or dividend return, maintaining a total return of 0.0%.<BR><BR>In the 4-year period, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>For the 5-year period, there was also no change in price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Kronox Lab has declared a dividend, the total returns over the various periods indicate a mixed performance, with significant negative returns in the short term and minimal returns over the longer term.